{"id":1059,"date":"2026-06-09T05:34:00","date_gmt":"2026-06-09T12:34:00","guid":{"rendered":"https:\/\/www.getasecondopinion.ai\/blog\/?p=1059"},"modified":"2026-06-11T17:35:03","modified_gmt":"2026-06-12T00:35:03","slug":"fda-accepts-first-in-silico-drug-development-tool-under-istand-program-to-help-predict-drug-induced-liver-injury","status":"publish","type":"post","link":"https:\/\/www.getasecondopinion.ai\/blog\/news\/fda-accepts-first-in-silico-drug-development-tool-under-istand-program-to-help-predict-drug-induced-liver-injury\/","title":{"rendered":"FDA Accepts First In Silico Drug Development Tool Under ISTAND Program to Help Predict Drug\u2011Induced Liver Injury"},"content":{"rendered":"\n

The U.S. Food and Drug Administration has taken an important step toward modernizing how new medicines are evaluated before they ever reach human testing. In early June 2026, the agency announced that it accepted the first Letter of Intent for an in silico, or computer\u2011based, drug development tool designed to help predict drug\u2011induced liver injury. This marks the first time such a digital model has entered the FDA\u2019s ISTAND Program, a pathway created to evaluate innovative scientific tools that fall outside traditional drug development methods.<\/p>\n\n\n\n

Drug\u2011induced liver injury, often shortened to DILI, is one of the biggest reasons drug candidates fail during development. It can cause clinical trials to stop early and can even prevent promising treatments from ever reaching patients. Because of this, researchers and regulators have long looked for better ways to predict liver toxicity before a drug is tested in people. The newly accepted tool aims to help fill that gap by using artificial intelligence to compare the chemical structure of a new drug with drugs already known to cause liver problems.<\/p>\n\n\n\n

This development is part of a broader shift in the pharmaceutical world toward using advanced computer models, artificial intelligence, and other digital technologies to improve safety predictions. It also reflects the FDA\u2019s ongoing interest in reducing reliance on animal testing and speeding up the development of safe, effective treatments.<\/p>\n\n\n\n

What the FDA Accepted and Why It Matters<\/strong><\/h2>\n\n\n\n

The tool accepted into the ISTAND Program is an AI\u2011driven digital liver model. In simple terms, it is a computer simulation of how the human liver might react to a new drug. Instead of relying only on lab experiments or animal studies, the model uses patterns learned from existing drugs with known liver risks. By comparing chemical structures, the model attempts to estimate whether a new drug might cause similar problems.<\/p>\n\n\n\n

This matters because predicting liver injury is notoriously difficult. Even drugs that look safe in early testing can cause unexpected liver problems once they reach human trials. The FDA notes that current methods do not reliably predict human risk, which is why DILI remains a major cause of drug development failures. A tool that improves early predictions could help researchers avoid costly dead ends and focus on safer drug candidates.<\/p>\n\n\n\n

The acceptance of this tool into the ISTAND Program does not mean it is fully approved for regulatory use yet. Instead, it marks the first step in a three\u2011stage qualification process. The developer must now submit a detailed qualification plan, followed later by a full qualification package. Only after completing all stages could the tool be officially recognized for use in regulatory submissions.<\/p>\n\n\n\n

Still, being accepted into the program is a significant milestone. It signals that the FDA sees potential value in the technology and is willing to work with developers to evaluate it thoroughly.<\/p>\n\n\n\n

What Is the ISTAND Program?<\/strong><\/h2>\n\n\n\n

The ISTAND Program, short for Innovative Science and Technology Approaches for New Drugs, was created to evaluate new types of drug development tools that do not fit into existing FDA qualification programs. These tools can include digital models, artificial intelligence systems, novel laboratory methods, and other emerging technologies that could help improve drug development.<\/p>\n\n\n\n

The program exists because drug development is changing rapidly. Traditional tools like animal studies, biomarkers, and clinical assessments are still important, but they are not always enough to answer complex safety questions. New technologies can offer fresh insights, but they need a clear pathway for evaluation. ISTAND provides that pathway.<\/p>\n\n\n\n

Examples of tools that might be considered under ISTAND include:<\/p>\n\n\n\n